Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction.
Collaborators (239)
Xu YS, Gu DF, Jia X, Chen Z, Sun JL, Chen J, Yu XH, Wang JH, Wang N, Zheng RP, Zhang SH, Liu CX, Sun LH, Zhao YC, Lin Y, Huang JB, Hu DY, Yang XC, Liu YZ, Gao MM, Zhang P, Deng CX, Liu Y, Li ZQ, Shi YQ, Hu TS, Chen YZ, Tan S, Zhao WR, Deng GL, Huang WJ, Zhang JC, Yu H, Shi QS, Wang XZ, Jiang B, Pan XR, Li L, Pu PL, Shu MQ, Xu QL, Zhang JH, Ding WH, Li L, Yang JJ, Su JL, Zhao WD, Liu X, Li LJ, Yang JF, Wang QS, Huang TG, Li LF, Zhou LJ, Guo JX, Li WH, Li ZP, Zhang XG, Peng XM, An YW, Shu J, Ma LT, Ge H, Zhang MJ, Lv ZR, Li JH, Yang JW, Zhang L, Cheng YL, Chen JG, Zhou CW, Zhang HH, Huang YL, Qu XF, Li JJ, Guo H, Wang GX, Hao SZ, Li SJ, Chang HS, Zhou SM, Liang HQ, Cao SJ, Liu JG, Yang J, Zhao MY, Lv Y, Xu SL, Wang ZL, Zhao SP, Li XP, Luo XL, Li YP, Lei Y, Fan SQ, Wang LH, Zhao LJ, Zhao YC, Xue SW, Li J, Xu SY, Cao YG, Tong BG, Wang W, Xu SK, Chen HZ, Guo WL, Wang LJ, Yan XM, Jing XF, Wang CH, Tang BX, Bai H, Li L, Liu Y, Li YP, Mei F, Yuan KZ, Zhang Y, Sun YR, Chen L, Xue SR, Wang JP, Li B, Liu ZM, Shen LH, Liang JR, Zhang Y, Song YL, Sun YM, Wang Z, Xu YH, Zhang WJ, Mu RQ, Li KQ, Wei YP, Wang SM, Fan YJ, An KY, Guo J, Li AP, Zeng DY, Huo HY, Chen Y, Song LX, Jiang BQ, Guo DJ, Chen H, Li L, Yin YQ, Mao YM, Miao L, Guo YJ, Li SJ, Cui SS, Diao Q, You XM, Jiang B, Zhu LT, Liu JM, Fang L, Lin SG, Chen LY, Huang WH, Zheng ZG, Ke YN, Wang Y, Wang QS, Liang H, Jia RY, Wang T, Liu CX, Gen QJ, Duan BX, Fang CQ, Wang JY, Chang ZW, Qi Y, Wang X, He WS, Ye P, Liu YC, Li CL, Ye JJ, He BX, Zhang XY, Hong XF, Shi RG, Wei WL, Sun JJ, Li ZC, Zhang XJ, He P, Gao W, He YJ, Zhang HB, Li ND, He XN, Chen GL, Wang JL, Liang GF, Dai GZ, Wang Q, Jin HY, Li Y, Wei LP, Qiao L, Gao SS, Wang S, Fang Q, Tao SQ, Chen ZJ, Gong LS, Li JZ, Xu YS, Jiang BQ, Shen LH, Liang SL, Huang YL, Chen YZ, Lu ZR, Kou WR, Wang ZL, Dai GZ, Zhang JH, Guo JX, Zeng DY, Lin SG, He BX, Wu YF, Wu XG, Wang JL, Lu ZL, Kou WR, Du BM, Wu YF, Li Y, Qin XW, Chen BL.
Fuwai Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, Peoples Republic of China.
Results of well-controlled prospective clinical trials showed the efficacy of lipid-lowering therapies in the reduction of cardiovascular (CV) events in western populations, but they were not reported with a Chinese population. This multicenter study was conducted to determine the effects of Xuezhikang (XZK), a partially purified extract of red yeast rice, on lipoprotein and CV end points in Chinese patients who experienced a previous myocardial infarction. Nearly 5,000 of these patients with average low-density lipoprotein cholesterol levels at baseline were randomly assigned either to placebo or to XZK daily for an average of 4.5 years. The primary end point was a major coronary event that included nonfatal myocardial infarction and death from coronary heart disease. Frequencies of the primary end point were 10.4% in the placebo group and 5.7% in the XZK-treated group, with absolute and relative decreases of 4.7% and 45%, respectively. Treatment with XZK also significantly decreased CV and total mortality by 30% and 33%, the need for coronary revascularization by 1/3, and lowered total and low-density lipoprotein cholesterol and triglycerides, but raised high-density lipoprotein cholesterol levels. In conclusion, long-term therapy with XZK significantly decreased the recurrence of coronary events and the occurrence of new CV events and deaths, improved lipoprotein regulation, and was safe and well tolerated.
PMID: 18549841 [PubMed - indexed for MEDLINE]